Cell . Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

[tetano]

Cell


. 2020 Aug 6;182(3):713-721.e9.
doi: 10.1016/j.cell.2020.06.008. Epub 2020 Jun 6.
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2


Hui Wang ¹ , Yuntao Zhang ¹ , Baoying Huang ² , Wei Deng ³ , Yaru Quan ⁴ , Wenling Wang ² , Wenbo Xu ² , Yuxiu Zhao ¹ , Na Li ¹ , Jin Zhang ¹ , Hongyang Liang ¹ , Linlin Bao ³ , Yanfeng Xu ³ , Ling Ding ¹ , Weimin Zhou ² , Hong Gao ³ , Jiangning Liu ³ , Peihua Niu ² , Li Zhao ² , Wei Zhen ² , Hui Fu ¹ , Shouzhi Yu ¹ , Zhengli Zhang ¹ , Guangxue Xu ⁵ , Changgui Li ⁶ , Zhiyong Lou ⁷ , Miao Xu ⁸ , Chuan Qin ⁹ , Guizhen Wu ¹⁰ , George Fu Gao ¹¹ , Wenjie Tan ¹² , Xiaoming Yang ¹³



Affiliations

• PMID: 32778225
• DOI: 10.1016/j.cell.2020.06.008

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.

Keywords: BBIBP-CorV; SARS-CoV-2; inactivated vaccine.